Expresión de STAT3 y respuesta a pirimetamina en un glioblastoma.
STAT3 expression and pyrimethamine response in a glioblastoma.
Barra lateral del artículo
PDF
FLIP
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Contenido principal del artículo
.
Descargas
Detalles del artículo
Cooper LA, Gutman DA, Chisolm C, Appin C, Kong J, Rong Y, et al. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol. 2012;180(5):2108-19.
Takakura A, Nelson EA, Haque N, Humphreys BD, Zandi-Nejad K, Frank DA, et al. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. Hum Mol Genet. 2011;20(21):4143-54.
Kohsaka S, Wang L, Yachi K, Mahabir R, Narita T, Itoh T, et al. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol Cancer Ther. 2012;11(6):1289-99.
Chen M, Osman I, Orlow SJ. Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells. Mol Cancer Res. 2009;7(5):703-12.
Giammarioli AM, Maselli A, Casagrande A, Gambardella L, Gallina A, Spada M, et al. Pyrimethamine induces apoptosis of melanoma cells via a caspase and cathepsin double-edged mechanism. Cancer Res. 2008;68(13):5291-300.
Bid HK, Oswald D, Li C, London CA, Lin J, Houghton PJ. Antiangiogenic activity of a small molecule STAT3 inhibitor LLL12. PLoS One. 2012;7(4):e35513.
De Groot JF, Liang J, Kong LY, Wei J, Piao Y, Fuller G, et al. Modulation of antiangiogenic resistance: Targeting the JAK/ STAT3 pathway in glioblastoma. J Clin Oncol. 2012;30 (suppl; abstr 2011).
Parsa AT. A newly identified transcriptional network for mesenchymal transformation of brain tumors: potential targets for therapeutic intervention. World Neurosurg. 2010;73(5):424.
